Britain and America have established a landmark bilateral deal that will ensure no duties on UK medicine exports entering the American market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has committed to raise funding on pharmaceuticals through the National Health Service (NHS). This commitment secures that import taxes on these crucial exports will remain at zero for a duration of three years.
This development is in response to recent threats to significantly raise tariffs on patented drug products, with increases floated up to 100%.
"This arrangement between the United Kingdom bolsters the worldwide climate for new treatments and introduces much-needed equity to U.S.–U.K. medicine commerce," an announcement said.
Economic Importance
Pharmaceuticals represent one of the Britain's biggest exports to the US, which is clearly the primary buyer for leading companies like GSK and AstraZeneca.
Statistics show that in the year leading up to last September, the UK shipped drugs valued at billions to the US. This value represented a significant portion of total UK exports in that period.
"This deal protects employment, increases funding and facilitates the UK to become a global hub for life sciences," the Business and Trade Secretary remarked.
Detailed NHS Changes
The agreement involves several notable pledges from the British government:
- Revised Affordability Limit: The UK will increase the price threshold at which it deems new medicines to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a aim to double overall public funding on treatments from 0.3% of GDP to 0.6% over the following ten-year period.
- Refund Ceiling: The percentage drug companies must refund to the NHS to stay within budget will be limited at fifteen percent. Previously, refunds topped twenty percent.
Broader Context
This agreement follows a long-running row between the drug companies and the UK government over spending levels and approval rates.
This friction were intensified by claims that American customers were paying a premium for the same drugs than patients in the other developed nations.
In recent months, several significant drug company projects in the UK have been paused or scrapped, while substantial expansions have been pledged toward US facilities.
A senior figure acknowledged that the NHS must increase expenditure on medicines, noting that its spending on drugs had decreased as a percentage of its overall budget over the previous ten-year period.
